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Abstract: Extracts of olive leaf, green coffee bean and beetroot may deliver cardiovascular 
benefits. This study sought to evaluate the effects of regularly consuming a combination of 
these extracts on blood pressure (BP), arterial compliance, blood lipids, blood glucose and 
insulin sensitivity. A double-blind randomised placebo-controlled crossover trial was 
conducted in adults with untreated high normal or borderline elevated BP. They were 
randomised to take an active supplement, comprising 500 mg olive leaf extract, 100 mg 
green coffee bean extract and 150 mg beet powder, or a matching placebo twice daily for six 
weeks, followed by the alternate supplement for a further six weeks. Assessments of 24-h 
ambulatory BP (ABP), clinic BP arterial compliance (pulse-wave analysis), blood lipids, 
blood glucose and insulin were obtained at baseline and at the end of each treatment phase. 
Baseline clinic BP in 37 overweight middle-aged men and women who completed the trial 
averaged 145/84 mmHg. There was no significant effect of treatment on ABP or any other 
outcome measure. The failure to confirm prior evidence of the antihypertensive benefits of 
these extracts emphasises the importance of placebo control and the value of ABP 
monitoring. Further dose-response evaluation of olive leaf, green coffee bean or beetroot 
extracts is required to confirm or refute the purported benefits.  
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1. Introduction 
Mediterranean societies have used olive tree leaves (Olea europaea L.) in traditional medicine. The 
olive leaf is believed to have antihypertensive, hypocholesterolemic, hypoglycaemic and anti-
inflammatory properties, which may be mediated by oleuropein, the predominant bioactive compound 
in olive leaf, and/or by other polyphenolic constituents [1–5]. Susalit et al. [3] reported reductions in 
systolic (SBP) and diastolic (DBP) pressure of 11.5/4.8 mmHg in untreated hypertensive adults after 
taking an olive leaf extract (1,000 mg/d) for eight weeks. A similar magnitude of BP reduction was also 
reported in a twins study after consuming the same dose of olive leaf extract daily for six weeks [2]. 
Each study also reported reductions of LDL cholesterol. However, these studies lacked placebo 
comparisons; thus, further randomised placebo-controlled trials are needed to confirm the potential 
cardiometabolic health benefits of olive leaf extracts in humans.  
The constituents of olive leaf responsible for any antihypertensive or cholesterol lowering effects are 
yet to be fully identified; however, a wide variety plant polyphenols are known to have antihypertensive 
potential as a result of their ability to enhance arterial dilatation, primarily via increased nitric oxide 
(NO) production in endothelial cells. Sources of these bioactives include decaffeinated green coffee bean 
extract and beetroot, as well as olive leaf. Chlorogenic acid, the major vasoactive ingredient in green 
coffee bean extract, has been shown to have a dose-dependent antihypertensive effect (up to 4.7/3.2 mmHg 
over 28 days) in untreated mildly hypertensive men; the reduction was significant at 93 mg/day (50 mg 
of chlorogenic acid) [6]. Chlorogenic acid appears to increase NO bioavailability, which could account 
for its BP lowering effects [7]. Likewise, beetroot juice has been recently acknowledged as an excellent 
source of nitrate, which can be retroconverted to NO, with the potential to enhance vasodilatation; acute 
reduction of BP has been reported with as little as 100 g of beetroot juice [8,9]. 
Clinic BP recordings, as used in the abovementioned studies, are highly variable, subject to artefacts 
(e.g., white coat hypertension) [10] and undergo regression to the mean with repeated measurement. All 
of these artefacts can be minimised through the use of 24-h ambulatory BP monitoring (ABPM), together 
with average daytime and nocturnal ABPM [10]. This gold standard approach to the assessment of BP 
change is yet to be applied in clinical trials evaluating the antihypertensive efficacy of olive leaf, green coffee 
bean or beetroot extracts, either alone or in combination.  
The present study sought to confirm the antihypertensive efficacy of the olive leaf extract in a placebo 
controlled comparison using 24-h ABPM in adults with mildly elevated, but untreated BP. In addition, 
it aimed to evaluate the effect of regular twice daily consumption of a novel formulation, which 
combined 500 mg of the olive leaf extract, 100 mg of green coffee bean extract (equivalent to 46.5 mg 
of chlorogenic acid) and 150 mg of beet powder in a single tablet on 24-h, daytime and nocturnal ABP. 
We hypothesised that this combination of extracts would have additive or synergistic effects on BP, LDL 
cholesterol glucose and insulin sensitivity. Evaluating the combined efficacy of dietary supplements that 
are available individually has potential implications for consumers desirous of obtaining a more potent 
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formulation [11]. The results of this study were intended to inform the development of a more potent 
supplement for BP management. 
2. Experimental Section  
2.1. Study Design  
A 12-week randomised, double-blind, placebo-controlled cross-over human dietary intervention trial 
with the combined formulation (as described above) or matching placebo (of identical appearance) was 
conducted at the Hunter Medical Research Institute, Clinical Nutrition Research Centre, University of 
Newcastle, in accordance with the principles of International Conference on Harmonisation’s Good 
Clinical Practice. The study was approved by the Human Research Ethics Committee of the University 
of Newcastle (H-2013-0131; approved on July 26, 2013), registered with the Australia and New Zealand 
Clinical Trials Registry (ACTRN12613000841774) and the Therapeutic Goods Administration of Australia.  
2.2. Study Population  
Volunteers residing in the Hunter region of New South Wales, Australia, were recruited from the 
general public via the Hunter Medical Research Institute research volunteer registry and public media 
announcements. All volunteers provided written informed consent prior to commencing the trial.  
Inclusion criteria were age 18–80 years, body mass index (BMI) between 20 and 35 kg/m2 (inclusive) 
and BP recorded at baseline/screening Visit 1 between 130–160 mmHg systolic and 85–100 mmHg 
diastolic. Exclusion criteria were as follows: (1) smokers or taking nicotine therapy; (2) taking 
antihypertensive medication or insulin; (3) pregnant or currently breastfeeding; (4) unwilling to wear the 
ABP monitor or undergo BP monitoring for 24 h; (5) unwilling to maintain habitual diet and physical 
activity during the intervention; (6) currently consuming dietary supplements containing extracts of olive 
leaf, green coffee bean or beet. 
2.3. Assessment Protocol  
Enrolled participants were required to visit HMRI on 6 occasions over 12 weeks, as shown in  
Figure 1. They attended the clinic at Visits 1, 3 and 5 following an overnight fast of 8 h. Volunteers were 
screened for eligibility at baseline, including assessment of clinic BP, arterial compliance (AC), 24-h 
ABP, fasting blood lipids, glucose and insulin, before being randomised to active treatment or a matching 
placebo. After returning their ABP monitors, they received the supplements to which they had been 
randomised and were instructed to maintain their habitual diet and physical activity throughout the 
intervention. Allocation to either treatment phase was based on randomisation by the minimisation 
method (age, gender and BMI) to ensure well-balanced groups in the first intervention phase [12]. 
Outcome measures were obtained after Week 6 and Week 12 at Visits 3 and 5. At Visit 4 in Week 6, 
following the measurement of 24-h ABPM, participants crossed over to the other treatment.  
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Figure 1. Outline of study design. During baseline/screening Visit 1 (Week 0), participants 
underwent assessments of body mass index (BMI), clinic blood pressure (BP), arterial 
compliance (AC), 24-h ambulatory BP (BP monitors), fasting blood lipids, glucose and 
insulin levels to confirm suitability before randomisation to treatment. These assessments 
were repeated at Visit 3 (Week 6), before participants switched over to the alternate 
treatment (Visit 4, Week 6) and again at Visit 5 (Week 12). 
 
2.4. Supplement and Treatment Regime  
The combined formulation and placebo were delivered in tablets of identical appearance. The active 
tablet was comprised of 500 mg of olive leaf extract (Benolea® EFLA®942, Frutarom Ltd.; comprises  
16%–24% oleuropein and ≥30% other polyphenols), 100 mg of green coffee bean extract (Svetol™, 
Naturex; comprised of 45%–50% chlorogenic acid, 10%–15% 5-caffeoylquinic acid, 50%–55% other 
polyphenols and 0%–2% caffeine) and 150 mg of Sensient® No.03600 beetroot powder per tablet. The 
placebo tablets comprised inert excipients (microcrystalline cellulose, stearic acid, cellulose powder, 
croscarmellose sodium and silicon dioxide).  
Participants were instructed to take 2 tablets daily, preferably at the same time with meals, and to 
record each intake in the assigned supplement diary. If a dose was missed, participants were requested 
to indicate the reason for missing and not carrying over the dose to the next day. Any changes in 
medication and/or dietary supplement intake during the intervention were to be self-reported in the 
supplement diary. At the end of 6 weeks, the bottle, diary and any unused tablets were returned. At the 
end of the trial, all tablets were manually counted and tallied with the corresponding diary records to 
monitor compliance.  
2.5. Blinding  
The olive leaf formulation and placebo tablets were identical in appearance, and each was dispensed 
in sealed white opaque containers, which were identifiable only by code numbers. An independent 
investigator randomised participants to treatments and assigned container code numbers. The 
investigational product was safely stored in a locked and limited access area. Trial investigators 
remained blinded until all data analysis had been performed. 
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2.6. Outcome Assessments 
2.6.1. Resting Clinic Blood Pressure and Arterial Compliance 
Standing height and body weight were measured before vascular assessments commenced. Seated 
BP, heart rate (HR) and AC assessments were performed after resting in a seated position for 10 min. 
Four consecutive readings were taken at 5-min intervals by automated oscillometry using a standard BP 
cuff over the left brachial artery (to assess BP and HR) and a tonometer (for pulse wave analysis of AC) 
positioned perpendicularly over the right radial artery with a sensitivity of at least 18% (to assess large 
and small artery elasticity indexes) using a Cardiovascular Profiler (HDI Cardiovascular Profiler 
CR2000 Minnesota, USA). BP measurements were performed by a single investigator, in accordance 
with the guidelines [13]. Discarding the first reading, an average of the remaining measurements was 
recorded for analysis. If average BP was greater than 160/100 mmHg at the baseline/screening Visit 1 
(Week 0), the participant would not be included in the trial and referred to their health professional for 
further evaluation.  
2.6.2. 24-h Ambulatory Blood Pressure Monitoring 
An appropriately-sized BP cuff was placed firmly around the upper non-dominant arm, centred over 
the brachial artery, with the ABP monitor (TM-2430, A & D Medical, Australia) worn on a waist strap. 
ABP monitors were programmed to record at 15-min intervals during the day (07.00–22.00 h) and at  
30-min intervals at night (22.00–07.00 h). The BP readings were programmed not to display to minimise 
the influence of the knowledge of the participant. The cuff and monitor were removed briefly for bathing 
or water-based activities and remained in place at all other times during the 24-h recording period. Each 
participant was assigned the same monitor and cuff size on each occasion. Participants also kept an 
activity diary to enable BP values to be related to their activities. The 24-h ABP data were downloaded 
and analysed using Doctor Pro 3 for Windows™ (TM-2430; version 3.03.00, A & D Medical, Australia). 
2.6.3. Biochemistry 
Fasting blood samples were collected by a certified phlebotomist at the Hunter Area Pathology 
Services, John Hunter Hospital, New South Wales, Australia, and sent to the Hunter Area Pathology 
Services laboratory for analyses of fasting serum lipids, glucose and insulin levels. The Homeostasis 
Model Assessment of Insulin Resistance (HOMA-IR) Index was determined by dividing the product of 
glucose and insulin levels by 22.5 [14]. 
2.7. Sample Size and Statistical Analysis 
This study was powered to detect differences between the combined formulation and placebo 
treatment. Assuming no order effect with the 2-way randomisation and no carry-over effect, a total of 
34 completers would give 80% power to detect a significant (p < 0.05) difference in average 24-h ABP 
of at least 3/2 mmHg (SBP/DBP). Forty participants were recruited to allow for attrition.  
All statistical analyses were performed on IBM® SPSS® Statistics Version 21.0 (Chicago, Illinois, 
USA). Data were checked for: (1) an order effect with the crossover design by comparing the treatment 
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difference (i.e., active, placebo) between those randomised initially to active treatment (Group 1) and 
those who received the placebo (Group 2); and (2) a difference in the measures of Group 1 and the group 
at baseline using t-tests (data not shown). In the intention-to-treat analysis, the effect of treatment on the 
primary outcome was the mean within-subject difference in ABPM between the active and placebo 
treatments, assessed from averaged 24-h daytime and nocturnal measurements of SBP, DBP, HR and 
mean arterial pressure (MAP) at the end of each 6-week intervention phase. This was determined using 
paired t-tests. Secondary outcomes (clinic BP, HR and AC, fasting serum lipids, glucose, insulin and 
HOMA-IR) were similarly tested; however, a modified Bonferroni adjustment was made to the levels 
of significance for multiple comparisons. 
There were sufficient numbers in each treatment arm to additionally perform a parallel comparison; 
independent t-tests were used to compare pre-post treatment differences in the active and placebo arms 
during the first intervention phase. In addition, we determined whether there were any treatment 
differences between sexes, as there was a good gender split. 
Figure 2. Consolidated Standards of Reporting Trials (CONSORT) diagram. 
 
3. Results  
3.1. Participant Disposition 
The study was conducted between September and December, 2013. Figure 2 shows the flow of 
participants from recruitment to data analysis. Of the 52 participants who were invited to a 
screening/baseline visit, 13 participants failed to meet the inclusion criteria for the study. Two of these 
had been placed on antihypertensive medication before their screening/baseline visit. The remaining 11 
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excluded participants failed to meet the inclusion criterion for clinic BP. Of the 39 participants who were 
enrolled, 37 completed the 12-week intervention. The two withdrawals occurred prior to the first 
assessment point in Week 6. One participant commenced antihypertensive medication, and one 
participant withdrew due to work commitments. Consequently, 37 participants completed all assessment 
time points and were included in the primary and secondary outcomes analyses. Participant compliance 
with the intervention was greater than 97% for both the combined formulation arm (98.5% ± 0.05%) and 
placebo arm (97.6% ± 0.05%); therefore, all 37 datasets were included for analysis.  
Baseline characteristics of the participants are shown in Tables 1–3. Participants were slightly 
overweight middle-aged adults with mildly-elevated clinic BP and 24-h ABP. With the exception of 
total cholesterol, their glucose, insulin, triglycerides, HDL and LDL cholesterol were within the 
acceptable ranges set forth by the National Heart Foundation of Australia and the Cardiac Society of 
Australia and New Zealand [15,16]. There were no differences in baseline characteristics between those 
randomised initially to active or placebo treatments.  
Table 1. Participant characteristics, clinic BP (blood pressure), HR (heart rate) and AC 
(arterial compliance) at baseline (Week 0) and at the end of the active phase and placebo 
phase (n = 37). SBP, systolic BP; DBP, diastolic BP.  
 Baseline 
End of Active 
Phase 
End of 
Placebo Phase 
Difference 
(Active, Placebo) 
 Mean ± SD Mean ± SEM Mean ± SEM Mean ± SEM p 
Gender (male/female) 20/17        
Age (years) 58.5 ± 10.7        
BMI (kg/m2) 27.2 ± 3.7 27.3 ± 0.6 27.3 ± 0.6 0.05 ± 0.06 0.382 
Clinic SBP (mmHg) 145.4 ± 7.8 135.3 ± 1.6 133.9 ± 1.5 1.41 ± 1.44 0.332 
Clinic DBP (mmHg) 84.4 ± 6.5 79.1 ± 1.2 80.0 ± 1.4 −0.94 ± 0.88 0.293 
Clinic HR (bpm) 66.6 ± 8.4 64.8 ± 1.5 64.0 ± 1.5 0.87 ± −0.58 0.233 
Clinic large artery 
elasticity index 
(mL/mmHg × 10) 
11.5 ± 4.1 12.8 ± 0.6 14.2 ± 0.7 −1.40 ± 0.56 0.017 
Clinic small artery 
elasticity index 
(mL/mmHg × 100) 
3.8 ± 2.1 4.2 ± 0.3 3.9 ± 0.3 0.28 ± 0.25 0.277 
Table 2. Average 24 h, daytime and nocturnal ABP at baseline and the end of each phase  
(n = 37). 
 Baseline 
End of Active 
Phase 
End of 
Placebo Phase 
Difference 
(Active, Placebo) 
 Mean ± SD Mean ± SEM Mean ± SEM Mean ± SEM p 
24-h ambulatory BP average 
SBP (mmHg) 135.8 ± 9.8 134.6 ± 1.8 132.8 ± 1.5 1.78 ± 1.18 0.138 
DBP (mmHg) 78.0 ± 6.3 79.7 ± 1.0 78.7 ± 0.9 1.05 ± 0.67 0.122 
MAP (mmHg) 98.2 ± 7.0 97.7 ± 1.2 96.3 ± 1.0 1.32 ± 0.79 0.102 
HR (bpm) 72.7 ± 8.2 72.4 ± 1.3 72.2 ± 1.3 0.24 ± 0.73 0.744 
Daytime BP average (07.00–22.00 h) 
SBP (mmHg) 140.6 ± 9.7 139.4 ± 1.8 137.2 ± 1.4 2.11 ± 1.33 0.123 
DBP (mmHg) 83.0 ± 6.5 82.8 ± 1.0 81.7 ± 1.0 1.16 ± 0.77 0.141 
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Table 2. Cont. 
 
Baseline 
End of Active 
Phase 
End of 
Placebo Phase 
Difference 
(Active, Placebo) 
 Mean ± SD Mean ± SEM Mean ± SEM Mean ± SEM p 
MAP (mmHg) 101.9 ± 7.10 101.4 ± 1.1 99.8 ± 1.0 1.60 ± 0.86 0.071 
HR (bpm) 75.4 ± 8.3 75.2 ± 1.4 74.9 ± 1.4 0.30 ± 0.84 0.724 
Nocturnal BP average (22.00–07.00 h) 
SBP (mmHg) 120.0 ± 11.7 119.6 ± 2.5 118.9 ± 2.1 0.68 ± 1.37 0.624 
DBP (mmHg) 70.2 ± 7.3 70.0 ± 1.4 69.2 ± 1.3 0.76 ± 0.84 0.375 
MAP (mmHg) 86.4 ± 8.4 86.2 ± 1.7 85.5 ± 1.4 0.73 ± 0.96 0.452 
HR (bpm) 64.2 ± 9.0 64.0 ± 1.4 64.3 ± 1.2 −0.32 ± 0.76 0.670 
Table 3. Blood biochemistry: total, HDL and LDL cholesterol, triglyceride, glucose and 
insulin and HOMA-index of insulin resistance at baseline and the end of each phase  
(n = 37). 
 Baseline 
End of Active 
Phase 
End of Placebo 
Phase 
Difference 
(Active, Placebo) 
Biochemistry Mean ± SD Mean ± SEM Mean ± SEM Mean ± SEM p 
Glucose (mmol/L) 5.18 ± 0.64 5.20 ± 0.11 5.15 ± 0.12 0.05 ± 0.07 0.440 
Insulin (mmol/L) 6.31 ± 2.90 7.32 ± 0.52 6.80 ± 0.58 0.51 ± 0.37 0.177 
HOMA-IR 1.40 ± 0.69 1.72 ± 0.14 1.58 ± 0.15 0.14 ± 0.10 0.173 
Triglycerides (mmol/L) 1.50 ± 1.11 1.34 ± 0.09 1.40 ± 0.12 −0.06 ± 0.08 0.449 
HDL cholesterol (mmol/L) 1.36 ± 0.26 1.29 ± 0.04 1.30 ± 0.04 −0.07 ± 0.02 0.499 
LDL cholesterol (mmol/L) 3.82 ± 0.93 3.78 ± 0.15 3.85 ± 0.16 −0.17 ± 0.10 0.504 
Total cholesterol (mmol/L) 5.80 ± 0.98 5.70 ± 0.15 5.83 ± 0.16 −0.13 ± 0.09 0.163 
Total/HDL ratio 4.39 ± 1.11 4.46 ± 0.20 4.63 ± 0.20 −0.07 ± 0.09 0.438 
3.2. Safety and Tolerability 
Throughout the 12-week intervention, there was only one serious adverse event (SAE), which 
involved hospitalisation of an individual who had been scheduled, prior to study enrolment, for a routine 
angiogram check, which required an overnight stay in the hospital. The purpose of the angiogram was 
to determine the appropriate size of an aortic stent to manage the participant’s aneurysm. The participant 
was readmitted to the hospital for the stent procedure and discharged without incident. The participant 
completed the intervention within the study timeframe. The SAE and subsequent follow-up was reported 
to the Human Ethics Research Committee of the University of Newcastle. 
There were four reported adverse events during the 12-week intervention. The complaints were vivid 
dreams (n = 1), gastrointestinal discomfort (n = 1), increased headache frequency and severity for a  
pre-existing migraine sufferer (n = 1) and improved taste (n = 1). Post hoc analysis revealed that the first 
three complaints occurred during the active treatment phase.  
3.3. Clinic Blood Pressure, Heart Rate and Arterial Compliance 
Clinic SBP and DBP readings at the end of the initial treatment phase were lower than those taken at 
the screening/baseline visit (Table 1). However, there were no order effects of treatment, and compared 
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with placebo, regular consumption of the combined formulation did not have an effect on clinic SBP, or 
DBP, or HR. Large artery elasticity tended to be lower at the end of the active treatment phase, but the 
difference was not significant following adjustment for multiple comparisons (Table 1). A parallel 
comparison was also made of the change from baseline to six weeks between those randomised initially 
to the combined formulation and those who received the placebo (see the table in the online Data 
Supplement). This comparison also failed to show any significance difference in the clinical measures 
of BP, HR and AC. Additionally, there was no gender difference in these measures. 
3.4. Ambulatory Blood Pressure Monitoring 
Compared with the placebo treatment, daily consumption of the combined formulation for six weeks 
did not affect 24-h, daytime nor nocturnal averages of ambulatory measures of SBP, DBP, MAP and HR 
(Table 2). Once again, there was no gender difference, and the analysis was not compromised by any 
order effect. A parallel comparison was also made of the change from baseline to six weeks between 
those randomised initially to the combined formulation and those who received the placebo (see the table 
in the online Data Supplement). This comparison also failed to show any significance difference in the 
ambulatory measures of SBP, DBP, MAP and HR. Additionally, there was no gender difference in  
these measures. 
3.5. Blood Biochemistry 
Fasting blood lipids, glucose levels and insulin sensitivity (HOMA-Index) were also unaffected by 
treatment (Table 3). Nor were any differences detected, once again, in a parallel comparison between 
active and placebo treatment arms in the first phase of the intervention. However, retrospective analysis 
revealed a gender difference in the crossover comparison. In men taking the combined formulation, there 
was a significant decrease in total cholesterol (active: 5.69 ± 0.21 mmol/L; placebo: 5.96 ± 0.21 mmol/L; 
change = −0.27 ± 0.09 mmol/L, p = 0.006; n = 20). This decrease in total cholesterol was accompanied 
by lowering of HDL cholesterol (active: 1.18 ± 0.04 mmol/L; placebo: 1.24 ± 0.05 mmol/L;  
change = −0.06 ± 0.0 mmol/L, p = 0.014) and LDL cholesterol (active: 3.86 ± 0.19 mmol/L; placebo: 
4.03 ± 0.20 mmol/L; change = −0.18 ± 0.09 mmol/L, p = 0.055). This result was not compromised by 
order effects or differences in baseline characteristics between Group 1 and Group 2. In women, the 
blood biomarkers remained unchanged following treatment. 
4. Discussion  
This is the first study to investigate the effects of supplementation with this combined formulation 
for six weeks on 24-h ABP, clinic BP and AC, blood lipids, glucose and insulin sensitivity in adults with 
mildly-elevated, but untreated, hypertension. We found no significant effect of the combined 
formulation on any physiological nor biochemical measures of cardiometabolic risk in our study. The 
daily dose of olive leaf extract (1000 mg) accounted for more than 60% of the active ingredients in the 
combined formulation and contained 160–240 mg of oleuropein (calculated from Benolea® EFLA®943 
Product Flyer). Similarly, in the study by de Bock et al., overweight men who were supplemented daily 
with 380 mg of olive leaf extract (containing 51.1 mg of oleuropein) for 12 weeks did not show 
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improvements in 24-h ABP or arterial elasticity, as determined by carotid intima-media thickness; 
however, these improvements would not be expected in a normotensive cohort [17]. The blood pressure 
lowering mechanisms of oleuropein are unclear, although in vitro evidence exits [18]. 
In published human studies on the effects of olive leaf extract on clinic BP [2,3] and biomarkers of 
diabetes [4,17], participants were supplemented daily for 8, 14 and 12 weeks, respectively. Susalit  
et al. [3] reported a small reduction in clinic SBP, triglycerides, total and LDL cholesterol compared to 
baseline values after eight weeks of olive leaf extract supplementation. While the dose of olive leaf 
extract used was the same as in the current study, the lack of a placebo comparison confounds the 
interpretation of their findings. Although they used a comparator drug, they doubled the dose of the 
comparator in patients who did not show a BP reduction at Week 2 of the eight-week intervention, 
thereby introducing a major methodological flaw in their evaluation. In another eight-week olive leaf 
extract supplementation study in borderline hypertensive monozygotic twins [2], Perrinjaquet-Moccetti 
et al. found a significant reduction in clinic BP (SBP, DBP and MAP) from baseline values at the sixth 
week of intervention, which returned to baseline after eight weeks. This reversion suggests that the 
antihypertensive effects may be transient and not sustainable. They also reported reductions in total and 
LDL cholesterol from baseline values following 1000 mg/day olive leaf extract consumption [2]. Both 
studies [2,3] were conducted by the supplement manufacturer. Once again, it is difficult to interpret the 
efficacy of olive leaf extract due to the lack of a placebo comparison. This introduces serious biases, 
particularly in relation to clinical assessment of BP, where the potential for a regression to the mean 
effect is well recognised [19]. This artefact was avoided in the present study by the use of ABP and a 
placebo control. Whilst there was a 10-mmHg reduction in clinic SBP from baseline to the end of the 
first six-week intervention phase, no such reduction occurred with ABP measurement. The lack of 
improvement in the 24-h, daytime and nocturnal ABP averages following active supplementation 
confirms the absence of BP lowering effects in the combined formulation in our present study. This was 
also evident from the clinic BP results in the present study, where a placebo comparison was used.  
In the present study, we noted a gender difference in the lipid response; we observed a 5% reduction 
in total cholesterol following six weeks of consumption of the combined formulation; however, this 
resulted from reductions of both HDL and LDL cholesterol. Nonetheless, in high-risk individuals, a 10% 
reduction of serum total cholesterol is estimated to confer an 8%–10% reduction in coronary heart 
disease mortality risk [20]. Interestingly, de Bock et al. [21] found a marked gender difference in the 
absorption and metabolism of oleuropein; males were more efficient at conjugating oleuropein.  
De Bock et al. [17] also found a 15%–20% improvement in insulin sensitivity, compared with placebo, 
following 12 weeks of daily supplementation with 380 mg of olive leaf extract (containing 51.1 mg of 
oleuropein) in overweight men with borderline insulin resistance (mean Matsuda Index = 5.12; Matsuda 
Index <4.3 indicates insulin resistance). Similarly, daily olive leaf extract supplementation (500 mg/day 
for 14 weeks) lowered HbA1C and fasting plasma insulin levels in adults with type 2 diabetes  
mellitus [4]. We did not see any improvements in insulin sensitivity following six weeks of 
supplementation with the combined formulation in our non-diabetic/insulin resistant cohort (mean 
HOMA-IR = 1.40), suggesting that a longer period of supplementation is needed to benefit those with 
insulin resistance.  
Even though olive leaf extract, at the dose given, may have been ineffective, the combined 
formulation also contained green coffee bean extract with chlorogenic acid, which has been shown to 
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have antihypertensive potential. Ferulic acid, a metabolite of chlorogenic acid, can enhance NO 
bioavailability in vitro [22], leading to endothelium-dependent vasodilatation, without affecting 
endothelium-independent sodium nitroprusside-induced vasodilatation [7]. The dose of green coffee 
bean extract used in the current study (which delivered 93 mg/day of chlorogenic acid) has been shown 
to lower BP in a dose-response study by Kozuma et al. [6]. Watanabe et al. [23] also reported an 
antihypertensive effect in untreated mildly hypertensive adults after consuming 140 mg/day of 
chlorogenic acid in a green coffee bean extract. However, the participants also underwent lifestyle 
modifications in a bid to lower their BP during the 12-week intervention (i.e., weight, dietary sodium 
and alcohol reduction and/or increased physical activity), which might have contributed to the BP 
reduction in the active treatment group. The lifestyle modifications were not standardised or monitored 
by the authors. Zhao et al. [7] cautioned that these two clinical trials were carried out in Far East Asia 
and suggested that ethnicity or differences in dietary customs may affect their reproducibility. In a recent 
acute intervention conducted in healthy adults in Australia (a predominantly Caucasian population) by 
Mubarak et al. [24], clinic SBP/DBP was lowered by 2.4/1.5 mmHg 60–90 min after consuming 400 
mg of pure chlorogenic acid mixed in water (equivalent to drinking two cups of coffee) compared with 
placebo (water). However, this antihypertensive effect was not accompanied by an increase in 
endogenous NO or enhancement of flow-mediated dilatation (FMD) of the brachial artery, a reliable 
NO-mediated endothelium-dependent vasodilatory response, thereby contradicting the abovementioned 
preclinical evidence [7]. We did not see any BP lowering changes following regular consumption of the 
combined formulation, indicating a lack of antihypertensive efficacy of a 93-mg daily dose of 
chlorogenic acid in our Caucasian participants. 
The dose of beetroot powder used in this study (300 mg/day) was considerably lower than the 
equivalent obtained from an efficacious dose of at least 100 g of beetroot juice in Hobbs et al. [9]. Plasma 
nitrate has a half-life of 6 h [25] and is excreted within 24 h [26]; hence, it was unlikely that the small 
amount of beetroot powder consumed in the combined formulation would have had an independent 
effect on BP, although it might have enhanced an anticipated effect of the other components at the  
doses administered.  
Considering that previous trials of the individual components of our combined formulation have 
claimed benefits for BP, blood lipids or insulin sensitivity, the outcome of our study is disappointing. 
One might argue that any potential effect could have been masked by a carryover effect of treatment in 
the crossover design, although there is no evidence to suggest that the bioactives in this combined 
formulation have persistent effects following wash-out. We had a sufficient number of participants 
completing the study to perform a parallel comparison of each treatment arm in the first six-week 
intervention phase, which confirmed a lack of effect on all outcome measures. Whilst unlikely, it is also 
possible that consuming a combination of three bioactive ingredients in a single tablet could have 
negatively impacted on the bioavailability of each individual ingredient or resulted in competing 
mechanistic actions on arterial function. This is a limitation that should be addressed by undertaking 
initial dose-response evaluations of the ingredients individually and using the results as a basis for 
formulating efficacious combinations.  
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5. Conclusions  
In conclusion, six weeks of daily supplementation with a combined formulation, comprising extracts 
of olive leaf, green coffee bean and beetroot, did not lower 24-h ABP nor clinic BP nor improve blood 
lipids, blood glucose nor insulin sensitivity in adults with borderline or mildly-elevated BP. However, 
evidence of efficacy from previous trials of olive leaf extract is questionable. Further evaluation of the 
individual ingredients is required in well-designed, randomised, double-blind, placebo-controlled trials 
in target populations. The choice of ethnicity should also be a consideration for future study designs. 
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